In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18\\u201350 years and RSV seropositive children 12\\u201324 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.
Subscribe (free):\\xa0Apple Podcasts,\\xa0Google Podcasts,\\xa0RSS,\\xa0email
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Progress toward\\xa0Poliomyelitis eradication\\xa0(CDC)
- Polio\\xa0by the numbers (JID)
- Influenza & COVID-19 vaccination coverage among\\xa0health care personnel\\xa0(CDC)
- Phase 1/2a\\xa0Safety & Immunogenicity of an adenovirus RSV Vaccine (JID)
- Receipt of first & second doses of\\xa0JYNNEOS vaccine\\xa0\\xa0(CDC)
- Distinguishing SARS-CoV-2\\xa0persistence and reinfection (CID)
- Remdesivir fact sheet\\xa0for providers (Veklury)
- Bebtelovimab fact sheet\\xa0for providers (FDA)
- Novavax triggers\\xa0potent neutralization\\xa0of Omicron sub-lineages (bioRxiV)
- Association\\xa0between physical activity & vaccination protective effect (BMJ)
- PAXLOVID patient eligibility\\xa0screening checklist (FDA)
- COVID-19 outcomes in\\xa0solid organ transplant recipients\\xa0who received monoclonal antibodies (Transplantation)
- Omicron BA.2.75.2\\xa0exhibits escape\\xa0from neutralizing antibodies (bioRxiV)
- Tocilizumab vs. Baricitinib\\xa0in hospitalized patients with severe COVID-19 (CMI)
- Dr. Griffin\\u2019s treatment guide (pdf)
- Contribute to\\xa0Floating Doctors fundraiser at PWB
- Letters read\\xa0on TWiV 949
- Timestamps by\\xa0Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv